CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment

We have used our established Glioblastoma cell models and gene expression analyses to characterize gene wild-type and CD70 knockdown GBM cell lines Overall design: We utilized early passage Glioblastoma cell lines derived from primary patient samples of Glioblastoma in our work, as these samples are enriched for Brain Tumor Initiating Cells (BTICs) that are believed to initiate tumor formation. Briefly, we transduced each cell line with either shGFP or shCD70-knockdown lentiviral vectors, and confirmed knockdown of CD70 by flow cytometry. These lines were minimally cultured, collected, and sent for RNA sequencing analysis.